Scott Baranoff, MD
Urology · Henderson, NVNPI 1356320261
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,794 of the $7,046 with a category attached, or 68.0%. It is spread thinly across 33 manufacturers, the largest accounting for just 16.3%. Reporting peaked in 2021 at $2,540 and has fallen 86.7% since, to $337 in 2024.
Across 217 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- Astellas Pharma US Inc$1K
- Verathon Inc.$800
- Sumitomo Pharma America, Inc.$656
- Boston Scientific$454
- Myriad Genetic Laboratories, Inc.$302
- plus $3K from 27 others
What the payments were for
- Consulting fees$1,92227%
- Speaking & faculty fees$2504%
- Food & beverage$4,79468%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 3 | $1,148 |
| Astellas Pharma US Inc | 60 | $1,100 |
| Verathon Inc. | 1 | $800 |
| Sumitomo Pharma America, Inc. | 29 | $656 |
| Boston Scientific | 10 | $454 |
| Myriad Genetic Laboratories, Inc. | 12 | $302 |
| Myovant Sciences Inc. | 12 | $297 |
| Dendreon Pharmaceuticals LLC | 12 | $264 |
| Cook Incorporated | 1 | $250 |
| Medtronic(2 entities) | 3 | $219 |
| Neotract Inc. | 2 | $156 |
| Urovant Sciences Inc | 8 | $144 |
| AbbVie | 6 | $131 |
| Endo Pharmaceuticals Inc. | 7 | $131 |
| Blue Earth Diagnostics | 5 | $112 |
| Coloplast | 4 | $103 |
| Pfizer | 5 | $94 |
| 180 Medical, Inc. | 5 | $83 |
| Urogen Pharma, Inc. | 3 | $72 |
| Merck | 3 | $62 |
| Johnson & Johnson(2 entities) | 3 | $57 |
| Telix Pharmaceuticals | 2 | $54 |
| Accord Healthcare, Inc. | 3 | $51 |
| Antares Pharma, Inc. | 3 | $50 |
| Rochester Medical Corporation | 3 | $50 |
| Ferring Pharmaceuticals Inc. | 3 | $47 |
| Tolmar Pharmaceuticals, Inc. | 2 | $30 |
| Axonics, Inc. | 2 | $29 |
| Acerus Pharmaceuticals Corporation | 1 | $26 |
| Procept Biorobotics Corporation | 1 | $20 |
| Mission Pharmacal Company | 1 | $20 |
| Amgen | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nubeqa$1,122
- NPD Clinical Study$800
- INTERSTIM$174
- REZUM$130
- SpaceOAR VUE System - 10mL$127
- GEMTESA$115
How this compares
$7,046 in reported general payments places this provider in the 60th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ElmironPentosan Polysulfate Sodium | 25 | $42,966 |
| GemtesaVibegron | 40 | $35,055 |
| MyrbetriqMirabegron | 32 | $33,308 |
| Tamsulosin Hcl | 598 | $9,106 |
| Testosterone | 28 | $6,908 |
| Silodosin | 53 | $4,900 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 204 | $3,976 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 67 | $3,297 |
| Oxybutynin Chloride ErOxybutynin Chloride | 125 | $3,214 |
| Finasteride | 250 | $2,856 |
| Dutasteride | 26 | $860 |
| Doxycycline Hyclate | 23 | $738 |
| Doxazosin Mesylate | 27 | $717 |
| Terazosin Hcl | 22 | $345 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $656 | $35,05540 claims |
| Astellas Pharma US IncMyrbetriq | $1,100 | $33,30832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 63 urology providers in Nevada.
Other urology in Henderson
- Casey McCrawHenderson$23K
- Guillermo PatinoHenderson$15K
- Jeffrey ZapinskyHenderson$7K
- Michael FinkelsteinHenderson$3K
- Adam RussonHenderson$2K
- Ralph LarsenHenderson$2K
- William SteinkohlHenderson$1K
- Eliot HorowitzHenderson$125
- Christopher EvansReno$184K
- Vijay GoliLas Vegas$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.